Mustang Bio 1 article

Mustang Bio is a cell-therapy biotechnology company whose scientific profile centers on solid tumor cell therapy. Its work connects MB-101 IL13Ralpha2 CAR-T cells with glioblastoma CAR-T therapy, placing the company in a specific mechanistic and therapeutic niche rather than a broad life-science category. That combination of HSV-1 oncolytic virotherapy with MB-109 CAR-T oncolytic virus combination helps distinguish the biotechnology profile of Mustang Bio.

Drug Discovery

September 23, 2026, 7:20 AM · 5 mins read

B cell non Hodgkin lymphoma pipeline grows as new trials target aggressive disease

A wave of clinical trials and new drugs is changing the B cell non Hodgkin lymphoma treatment field. More than seventy five companies are now moving over eighty therapies through the pipeline.